Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Oncol., 08 September 2025

Sec. Cancer Immunity and Immunotherapy

Volume 15 - 2025 | https://doi.org/10.3389/fonc.2025.1641399

This article is part of the Research TopicNew Horizons in Tumor Microenvironment Biology and Therapy: Implications for New Therapies, Volume IIView all 19 articles

Correction: TPL inhibits the invasion and migration of drug-resistant ovarian cancer by targeting the PI3K/AKT/NF-κB-signaling pathway to inhibit the polarization of M2 TAMs

This article is a correction to:

  1. TPL Inhibits the Invasion and Migration of Drug-Resistant Ovarian Cancer by Targeting the PI3K/AKT/NF-κB-Signaling Pathway to Inhibit the Polarization of M2 TAMs

    1. Read original article
Fuyin Le&#x;Fuyin Le1†Lilan Yang&#x;Lilan Yang2†Yiwen HanYiwen Han3Yanying ZhongYanying Zhong1Fuliang ZhanFuliang Zhan1Ying FengYing Feng1Hui Hu*Hui Hu1*Tingtao Chen,*Tingtao Chen1,3*Buzhen Tan*Buzhen Tan1*
  • 1Department of Obstetrics & Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
  • 2Department of Obstetrics & Gynecology, The First Affiliated Hospital of Nanchang University, Nanchang, China
  • 3Institute of Translational Medicine, Nanchang University, Nanchang, China

A Correction on
TPL inhibits the invasion and migration of drug-resistant ovarian cancer by targeting the PI3K/AKT/NF-κB-signaling pathway to inhibit the polarization of M2 TAMs

By Le F, Yang L, Han Y, Zhong Y, Zhan F, Feng Y, Hu H, Chen T and Tan B (2021) Front. Oncol. 11:704001. doi: 10.3389/fonc.2021.704001

There was a mistake in Figure 3 as published. In Figure 3C, there are instances of duplicated areas between some images due to carelessness. Specifically, these occur between: Migration-C and Invasion-Co-C; Invasion-C and Migration-12.5nM TPL; Invasion-C and Invasion-6.25nM TPL; Invasion-Co-C and Invasion-12.5nM TPL; Invasion-6.25nM TPL and Migration-25nM TPL; Invasion-6.25nM TPL and Migration-12.5nM TPL. The corrected Figure 3 appears below.

Figure 3
Panel A shows EdU, DAPI, and overlay images illustrating cell proliferation under different conditions. Panel B is a bar graph of cell proliferation rates, with variations across treatments. Panels C depict migration and invasion assays, showing cell behavior under various conditions. Panels D and E provide bar graphs comparing migration and invasion fold changes. Panels F and G display A2780/DDP cell counts at three and six hours, respectively, showing differences under specific treatments.

Figure 3. Tumor-associated macrophage (TAM) cell supernatant slightly improves the proliferation, migration, and invasiveness of A2780/DDP cells, but triptolide (TPL) reverses these effects. (A) TPL was diluted to varying concentrations with TAM cell supernatant, and then added to A2780/DDP cells; cell proliferative ability was measured 24 h later. (B) Quantitative analyses of the proliferative capacity of A2780/DDP cells are shown in (A). (C) Representative transwell migration and invasion assay of A2780/DDP cells after treatment with TPL. (D, E) Quantification of migratory and invasive capacities of A2780/DDP in (C). *P < 0.05, **P < 0.01, and ***P < 0.001. (F, G) Representative extracellular matrix-adhesion experiment using A2780/DDP cells treated with different concentrations of TPL for 3 or 6 h. *P < 0.05. ns, no significance.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: A2780/DDP cells, cisplatin (DDP) resistance, triptolide (TPL), PI3K/AKT/NF-κB- pathway, tumor-associated macrophages (TAMs)

Citation: Le F, Yang L, Han Y, Zhong Y, Zhan F, Feng Y, Hu H, Chen T and Tan B (2025) Correction: TPL inhibits the invasion and migration of drug-resistant ovarian cancer by targeting the PI3K/AKT/NF-κB-signaling pathway to inhibit the polarization of M2 TAMs. Front. Oncol. 15:1641399. doi: 10.3389/fonc.2025.1641399

Received: 05 June 2025; Accepted: 20 August 2025;
Published: 08 September 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Le, Yang, Han, Zhong, Zhan, Feng, Hu, Chen and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Tingtao Chen, Y2hlbnRpbmd0YW8xOTg0QDE2My5jb20=; Buzhen Tan, dGFuYnV6aGVuQHNpbmEuY29t; Hui Hu, aHVodWkyMDA4QDE2My5jb20=

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.